Skip to content

Study · Animal study (in vivo) · mouse · 2020

6 results

The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.

Zhang L, Zhang L, Li Y, Li L, Melchiorsen JU, Rosenkilde M, Hölscher C

Journal of Parkinson's disease1 Jan 2020Cited by 60 (Europe PMC)

PMID31958096 (opens in a new tab)DOI10.3233/jpd-191768 (opens in a new tab)PepBankPUB-31958096
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In the MPTP mouse model of Parkinson's disease, liraglutide improved MPTP-induced motor impairments.

    In plain wordsIn mice with a Parkinson's-like condition, liraglutide improved movement problems caused by the toxin MPTP.

    Peptide
    Liraglutide
    Outcome
    DecreaseMPTP-induced motor impairment
    Study

    mousen: not reported in source

    MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    both DA-CH5 and Liraglutide improved MPTP-induced motor impairments.
    1 context sentence
    Summary · context
    DA-CH5, exendin-4 and liraglutide were tested in the MPTP mouse model of PD.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In the MPTP mouse model of Parkinson's disease, liraglutide reversed the decrease in the number of tyrosine hydroxylase-expressing neurons in the substantia nigra.

    In plain wordsIn mice with a Parkinson's-like condition, liraglutide restored the number of dopamine-producing nerve cells that the toxin MPTP had reduced.

    Peptide
    Liraglutide
    Outcome
    IncreaseTyrosine hydroxylase-expressing neurons in substantia nigra
    Study

    mousen: not reported in source

    MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    the drugs reversed the decrease of the number of neurons expressing tyrosine hydroxylase (TH) in the SN
    2 context sentences
    Summary · context
    When comparing the neuroprotective effect of DA-CH5 with Liraglutide, a GLP-1 analogue, both DA-CH5 and Liraglutide improved MPTP-induced motor impairments.
    Summary · context
    DA-CH5, exendin-4 and liraglutide were tested in the MPTP mouse model of PD.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In the MPTP mouse model of Parkinson's disease, liraglutide alleviated chronic inflammation.

    In plain wordsIn mice with a Parkinson's-like condition, liraglutide reduced long-lasting inflammation in the brain.

    Peptide
    Liraglutide
    Outcome
    DecreaseChronic inflammation
    Study

    mousen: not reported in source

    MPTP mouse model of Parkinson's disease
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    alleviated chronic inflammation, reduced lipid peroxidation, inhibited the apoptosis pathway (TUNEL assay) and increased autophagy -related proteins expression in the substantia nigra (SN) and striatum.
    2 context sentences
    Summary · context
    When comparing the neuroprotective effect of DA-CH5 with Liraglutide, a GLP-1 analogue, both DA-CH5 and Liraglutide improved MPTP-induced motor impairments.
    Summary · context
    DA-CH5, exendin-4 and liraglutide were tested in the MPTP mouse model of PD.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In the MPTP mouse model of Parkinson's disease, liraglutide reduced lipid peroxidation.

    In plain wordsIn mice with a Parkinson's-like condition, liraglutide reduced a marker of oxidative damage.

    Peptide
    Liraglutide
    Outcome
    DecreaseLipid peroxidation
    Study

    mousen: not reported in source

    MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    reduced lipid peroxidation, inhibited the apoptosis pathway (TUNEL assay) and increased autophagy -related proteins expression in the substantia nigra (SN) and striatum.
    2 context sentences
    Summary · context
    When comparing the neuroprotective effect of DA-CH5 with Liraglutide, a GLP-1 analogue, both DA-CH5 and Liraglutide improved MPTP-induced motor impairments.
    Summary · context
    DA-CH5, exendin-4 and liraglutide were tested in the MPTP mouse model of PD.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In the MPTP mouse model of Parkinson's disease, liraglutide inhibited the apoptosis pathway as measured by TUNEL assay.

    In plain wordsIn mice with a Parkinson's-like condition, liraglutide reduced signs of programmed cell death in the brain.

    Peptide
    Liraglutide
    Outcome
    DecreaseApoptosis pathway (TUNEL assay)
    Study

    mousen: not reported in source

    MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    inhibited the apoptosis pathway (TUNEL assay) and increased autophagy -related proteins expression in the substantia nigra (SN) and striatum.
    2 context sentences
    Summary · context
    When comparing the neuroprotective effect of DA-CH5 with Liraglutide, a GLP-1 analogue, both DA-CH5 and Liraglutide improved MPTP-induced motor impairments.
    Summary · context
    DA-CH5, exendin-4 and liraglutide were tested in the MPTP mouse model of PD.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In the MPTP mouse model of Parkinson's disease, liraglutide increased autophagy-related protein expression in the substantia nigra and striatum.

    In plain wordsIn mice with a Parkinson's-like condition, liraglutide increased proteins that help brain cells clear damaged parts.

    Peptide
    Liraglutide
    Outcome
    IncreaseAutophagy-related protein expression
    Study

    mousen: not reported in source

    MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    increased autophagy -related proteins expression in the substantia nigra (SN) and striatum.
    2 context sentences
    Summary · context
    When comparing the neuroprotective effect of DA-CH5 with Liraglutide, a GLP-1 analogue, both DA-CH5 and Liraglutide improved MPTP-induced motor impairments.
    Summary · context
    DA-CH5, exendin-4 and liraglutide were tested in the MPTP mouse model of PD.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT02953665

Safety and Efficacy of Liraglutide in Parkinson's Disease

Cedars-Sinai Medical Centern = 633 Apr 2017 to 3 Aug 2022

Parkinson Disease

Trial pageClinicalTrials.govUpdated 7 Mar 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.